Thursday, July 07, 2016 9:38:27 PM
With a $12,500 retainer fee upon signing and the $10,000/month retainer fee for the other firm negotiating deals for the product line, one thing seems clear to me: RGBP truly believes its science and new discoveries are at a point advanced enough to engage others in striking deals, whether that is with Mexico and the HemaX clinical trials (which now have 3 month data on other blood applications testing) as well as the development for aplastic anemia and/or the NR2F6 small molecule research advancement which now has at least 2 matches for activation.
July - August should bring some very interesting news. Any agreement that is reasonable and gives the company enough cash for clinical phase I trials should have a positive effect on PPS as well.
Let's hope all goes well.
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM